PACB - パシフィック・バイオサイエンシズ・オブ・カリフォルニア （Pacific Biosciences of California Inc.）

MENLO PARK, Calif., April 21, 2022 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB ), a leading provider of high-quality, highly accurate sequencing solutions, today announced an expanded research collaboration with Children''s Mercy Kansas City, one of the nation''s top pediatric medical systems, to use the multi-omics capabilities of PacBio''s Sequel IIe system in the study of genetic disease. The research will apply direct methylation detection and Iso-Seq ™ full-length RNA sequencing in their study. A better understanding of the genetic underpinnings of rare disease may ultimately help drive diagnostic yield and potentially enhance care for patients. Children''s Mercy is a leader in using PacBio''s genomic sequencing technology, approaching 1,000 samples sequenced since 2020. "Our continued collaboration with Children''s Mercy is a great example of PacBio''s technology being used at breadth, depth, and scale," said Christian Henry, President and Chief Executive Officer of PacBio. "We believe the Sequel IIe system provides the world''s best genomes, and is capable of delivering the most complete methylomes and full-length RNA isoform sequencing.

MENLO PARK, Calif., April 21, 2022 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading provider of high-quality, highly accurate sequencing solutions, today announced an expanded research collaboration with Children’s Mercy Kansas City, one of the nation’s top pediatric medical systems, to use the multi-omics capabilities of PacBio’s Sequel IIe system in the study of genetic disease. The research will apply direct methylation detection and Iso-Seq ™ full-length RNA sequencing in their study. A better understanding of the genetic underpinnings of rare disease may ultimately help drive diagnostic yield and potentially enhance care for patients. Children’s Mercy is a leader in using PacBio’s genomic sequencing technology, approaching 1,000 samples sequenced since 2020.

MENLO PARK, Calif., April 21, 2022 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB ), a leading developer of high-quality, highly accurate sequencing solutions, today announced the release of a transformative capability to detect DNA methylation using the Sequel IIe and Sequel II Systems . This extends PacBio''s unique and highly capable HiFi sequencing technology to now include access to the epigenome, a second layer of genomic information often left unexplored due to fundamental limitations of common sequencing technologies. PacBio''s single-molecule approach provides a much more holistic view of molecular behavior during sequencing. Subtle patterns in this rich information allow detection of modified bases in native DNA during standard HiFi sequencing. As a result, scientists gain access to the epigenome with zero additional cost, effort, or complexity. This advance will unlock important new opportunities across a broad range of applications in fundamental and applied biological science. This update also includes a wide range of workflow improvements to enhance customer experience, such as simplified, unified, and accelerated library preparation workflows and consumables, live instrument performance monitoring, and on-instrument analysis support for recombinant adeno-associated virus (rAAV) genome sequencing, a rapidly growing biopharmaceutical application relevant to gene therapy and vaccine development research.

MENLO PARK, Calif., April 20, 2022 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) announced today that it will hold its quarterly conference call to discuss its first quarter 2022 financial results on Wednesday, May 4, 2022, at 5:00 pm Eastern Time.

Anyone thinking about buying shares should know them, too.

Anyone thinking about buying shares should know them, too.

Pune, April 05, 2022 (GLOBE NEWSWIRE) -- The market for next generation sequencing can be segmented based on product & services, technology, application, end-users and geography. The product segment can be categorized as Pre-Sequencing Products & Services, NGS Consumables, Platforms, & Services for Platforms, Sequencing Services and NGS Data Analysis, Storage, and Management (Bioinformatics). Next generation sequencing (NGS) Market by Regions Geographically, the market is segmented into North America, Europe, Asia-Pacific, and Rest of the World (Latin America (LATAM), and Middle East and Africa (MENA). North America accounted for the largest market share of the market followed by Europe. However, during the forecast period Asia-Pacific region is anticipated to record highest growth owing to wide penetration of the technology and technological advancement in NSG, increasing focus on drug discovery initiatives by healthcare and biopharmaceutical companies, investment by pharmaceutical and biotechnology companies in drug discovery are some of the key factors expected to drive the growth of next generation sequencing market.

PacBio (PACB) announced an agreement with Corteva Agriscience (CTVA) to develop custom, end-to-end workflows for plant, pest and microbial sequencing. "We are proud to provide a…

During the last session, Pacific Biosciences of California Inc. (NASDAQ:PACB)’s traded shares were 2.28 million, with the beta value of the company hitting 1.33. At the end of the trading day, the stock’s price was $10.94, reflecting an intraday loss of -2.58% or -$0.29. The 52-week high for the PACB share is $37.42, that puts … Does Pacific Biosciences of California Inc. (NASDAQ: PACB) Still Look Attractive After A -3.19% Selloff Last Week? Read More »

Pacific Biosciences of California Inc (PACB) shares closed this week 20.7% lower than it did at the end of last week. The stock is currently down 19.0% year-to-date, down 54.8% over the past 12 months, and up 230.9% over the past five years. This week, the Dow Jones Industrial Average fell 1.3%, and the S&P 500 fell 2.6%. Trading Activity Shares traded as high as $21.01 and as low as $15.58 this week.Trading volume this week was 10.6% higher than the 10-day average and 38.2% higher than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 2.7. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price lags the S&P 500 Index this week, lags it on a 1-year basis, and beats it on a 5-year basis The company's share price lags the Dow Jones Industrial Average this week, lags it on a 1-year basis, and beats it on a 5-year basis The company share price lags the performance of its peers in the Health Care industry sector this week, lags it on a 1-year basis, and beats it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 154.1% The company's stock price performance over the past 12 months lags the peer average by 556.1% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.

Huadi International Group (HUDI) -16%.Bone Biologics (BBLG) -12%.Reviva Pharmaceuticals (RVPH) -10%.Pacific Biosciences of California PACB -9% after reports lower than expected prelim

MENLO PARK, Calif., Jan. 11, 2022 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB ), a leading provider of high-quality, highly accurate sequencing platforms, today announced a collaboration with Genomics England to study PacBio''s technology for identifying genetic variants in unexplained rare disease cases. Genomics England was initially created to deliver the 100,000 Genomes Project the largest whole genome sequencing disease cohort of cancer and rare disease participants in the National Health Service (NHS). The study will re-sequence a selection of samples collected during Genomics England''s 100,000 Genomes Project, which were previously analyzed with short read sequencing technology. The study is intended to reveal potential operational and clinical benefits of long-read sequencing in identifying genetic mutations associated with rare diseases. "PacBio HiFi sequencing is a powerful tool for understanding the genetic underpinnings of rare disease, cancer, and other applications as it provides clinical researchers with the ability to view the genome more completely than other sequencing technologies," said Christian Henry, President and Chief Executive Officer of PacBio. "Our collaboration with Genomics England is part of a broader strategy to demonstrate the benefits of HiFi sequencing when attempting to identify rare diseases, and follows recent announcements of rare disease-focused research collaborations with Radboud University Medical Center ,